The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Intersection · Compounds × mislabelling

Compounds topics tagged mislabelling

Topics in Compounds carrying the tag mislabelling. Wrong compound, wrong strength, or wrong batch on the label.

19 topics

TopicParticipantsRepliesViewsActivity
Compounds this community declines to help with, and why — does this still hold?
Compounds this community declines to help with, and why — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SCALE ( N Engl J Med ,…
TGAVGDAT+3 7 26k 7h
AOD-9604 and the fragment hypothesis, revisited — does this still hold?
The question in the title: AOD-9604 and the fragment hypothesis, revisited — does this still hold? I will give what I have already checked below so nobody repeats it. Comparing FLOW ( N Engl J Med , 2024)…
NLKKNRPFI+7 11 31k 19h
Research-use-only status: what it means legally and practically
Research-use-only status: what it means legally and practically Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited in…
KFKLVSHVAF+72 81 44k 1d
Naming conventions for research peptides and the confusion they cause
Posting this under the heading it deserves: Naming conventions for research peptides and the confusion they cause Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with STEP 1 ( N…
ATNFPNDA+21 25 4.9k 22d
Coming back to: Reading a supplier's product description as a marketing document
Reading a supplier's product description as a marketing document Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in…
HBELCVHNDN+35 39 688 5mo
AOD-9604 and the fragment hypothesis, revisited
Posting this under the heading it deserves: AOD-9604 and the fragment hypothesis, revisited Everything below is what sits behind that. Comparing SURPASS-2 ( N Engl J Med , 2021) with SUSTAIN 6 ( N Engl J Med…
ARCDJBMRBR+40 44 2.8k 6mo
Sequence verification for an obscure compound: how it is done — what changed since
On the subject in the title: Sequence verification for an obscure compound: how it is done — what changed since Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please…
TNDBSOLGHF+100 108 1.3k 8mo
Reading a supplier's product description as a marketing document
On the subject in the title: Reading a supplier's product description as a marketing document Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim I…
SVTVMRZOIN+86 97 62k 8mo
Research-use-only status: what it means legally and practically — does this still hold?
Asking directly, because I could not find a straight answer: Research-use-only status: what it means legally and practically — does this still hold? Session topic: SELECT ( N Engl J Med , 2023). Please read…
DBETRT 2 309 9mo
Compounds this community declines to help with, and why
Compounds this community declines to help with, and why — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SCALE ( N Engl J Med , 2015) and…
MKJSMSRFF+81 87 35k 10mo
Why catalogue breadth is not evidence of anything — what changed since
Asking directly, because I could not find a straight answer: Why catalogue breadth is not evidence of anything — what changed since Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…
NEHFDBBKLG+62 66 26k 10mo
How to research a compound with no human data without deceiving yourself
Asking directly, because I could not find a straight answer: How to research a compound with no human data without deceiving yourself Session topic: STEP 2 ( Lancet , 2021). Please read it before posting; the…
FNSRMFSTRH+107 119 11k 12mo
Sequence verification for an obscure compound: how it is done
Sequence verification for an obscure compound: how it is done Writing it up because I had to work it out twice and would rather nobody else did. Comparing SUSTAIN 6 ( N Engl J Med , 2016) with SURMOUNT-1 ( N…
BNGVIAJVGE+104 114 10k 12mo
Second pass at: How to research a compound with no human data without deceiving yourself
Second pass at: How to research a compound with no human data without deceiving yourself Writing it up because I had to work it out twice and would rather nobody else did. Comparing STEP 1 ( N Engl J Med ,…
SVKBISCGP+64 71 2.5k 13mo
When "no data" is the complete and final answer
Asking directly, because I could not find a straight answer: When "no data" is the complete and final answer I have seen SURMOUNT-1 ( N Engl J Med , 2022) cited in support of a claim I do not think it…
NPNTPOSPNS+154 165 6.3k 15mo
Research-use-only status: what it means legally and practically — a second dataset
Research-use-only status: what it means legally and practically — a second dataset — setting out what I have, and where I think it stops being reliable. Comparing FLOW ( N Engl J Med , 2024) with SURPASS-2 (…
TWONMSRFF+109 125 2k 16mo
Revisiting: Melanocortin agonists: mechanism and the documented adverse profile
Posting this under the heading it deserves: Revisiting: Melanocortin agonists: mechanism and the documented adverse profile Everything below is what sits behind that. Comparing SURMOUNT-4 ( JAMA , 2024) with…
NATKBANDB+119 141 22k 20mo
Melanocortin agonists: mechanism and the documented adverse profile
Melanocortin agonists: mechanism and the documented adverse profile — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SURMOUNT-2 ( Lancet , 2023) and…
APAWCEBWGR+7 11 5.5k 20mo
Naming conventions for research peptides and the confusion they cause — one year on
Naming conventions for research peptides and the confusion they cause — one year on — setting out what I have, and where I think it stops being reliable. I have seen SURMOUNT-2 ( Lancet , 2023) cited in…
CPLCVSMSCV+1 5 181 2y